English 日本語

#Zasositinib

List of IR information related to "Zasositinib".

2 IR Posts
1 Companies
42 days ago Last Updated

Filters

Reset
Period:
Importance:
2 IR Posts
4502 Takeda Pharmaceutical Company Limited
2026/01/20
(Correction) Partial correction regarding “Zasositinib for Plaque Psoriasis, Oral Once Daily Administration Shows Improvement in Skin Lesions and Possibility to Open a New Era of Treatment: Breakthrough Phase 3 Clinical Trial Data”

In the Phase 3 clinical trial of Zasositinib, the primary endpoints were achieved at week 16, with more than half of patients reaching PASI 90 and approximately 30% achieving PASI 100 indicating complete clearance of skin lesions. Safety profile was favorable.

#TakedaPharmaceuticalCompanyLimited #product_announcement #Zasositinib
4502 Takeda Pharmaceutical Company Limited
2025/12/18
Innovative Phase 3 Clinical Trial Data Demonstrates Zasositinib, Administered Once Daily Orally for Plaque Psoriasis, Improves Skin Lesions and Opens a New Era in Treatment

Zasositinib (TAK-279) achieved primary endpoints in a Phase 3 clinical trial targeting patients with moderate to severe plaque psoriasis, with over half achieving PASI90 and approximately 30% achieving PASI100 at week 16.

Strategy/Investment,Other
#TakedaPharmaceuticalCompanyLimited #Zasositinib #NewProduct
Scroll to Top